Maintenance Combination Therapy

Maintenance Combination Therapy is a type of combination chemotherapy regimen, distinguished by its administration after initial induction therapy to sustain remission, delay disease progression, and improve survival outcomes in patients with responsive or stable disease.

308

Publications

17.9K

Citations

2.9K

Authors

1.3K

Institutions

Publications per year

2017–2026

92

Publications

308

1–5 of 308

Authors

2.9K

  1. CV
    Carla Visseren‐Grul

    Eli Lilly (United States), United States

    10 publications · 1.5K citations

    10

    h-index

  2. FD
    Filippo de Marinis

    European Institute of Oncology, Italy

    10 publications · 1.5K citations

    10

    h-index

  3. MR
    Martin Reck

    German Center for Lung Research, Germany

    10 publications · 1.7K citations

    10

    h-index

  4. WJ
    William J. John

    Eli Lilly (United States), United States

    10 publications · 2.6K citations

    10

    h-index

  5. CP
    Chandra P. Belani

    UPMC Hillman Cancer Center, United States

    9 publications · 1.6K citations

    9

    h-index

1–5 of 2.9K

Venues

  1. Journal of Clinical Oncology

    81 publications · 6.7K citations

    43

    h-index

  2. Cancer

    16 publications · 639 citations

    16

    h-index

  3. PubMed

    Repository · 20 publications · 870 citations

    13

    h-index

  4. Blood

    9 publications · 666 citations

    9

    h-index

  5. Annals of Oncology

    8 publications · 631 citations

    8

    h-index

1–5